Lisa Kelly-Croswell - Jul 18, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
Director
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Stock symbol
EIGR
Transactions as of
Jul 18, 2022
Transactions value $
$0
Form type
4
Date filed
7/19/2022, 07:02 PM
Previous filing
Jun 13, 2022
Next filing
Mar 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jul 18, 2022 Common Stock 30K $8.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal monthly installments over 36 months measured from July 18, 2022 subject to Reporting Person's continuous service status as of each such date.